Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
regadenoson + temozolomide
- Development stage
- Preclinical
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of regadenoson, a selective A2A adenosine receptor agonist and vasodilator, and temozolomide, an alkylating agent used in the treatment of brain tumors. This combination is being investigated for its potential to enhance temozolomide delivery to brain tumors by transiently disrupting the blood-brain barrier.
02
Targets
ADORA2A (Adenosine A₂A Receptor)DNA
Beyond the preview
Go deeper on regadenoson + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on regadenoson + temozolomide.